Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda (TEST4TPT)

10. November 2026 aktualisiert von: Christiaan Mulder, KNCV Tuberculosis Foundation

TEST4TPT: AI Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda

The Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda (TEST4TPT) project will evaluate a person-centered approach to improve access to tuberculosis infection (TBI) testing and linkage to tuberculosis preventive treatment (TPT) in Mozambique, Tanzania, and Uganda. The project will generate evidence on the feasibility, acceptability, clinical utility, diagnostic and operational performance, and implementation of a novel point-of-care TBI testing approach, including home- or community-based testing and artificial intelligence (AI)-assisted reading. By bringing testing closer to people at increased risk of tuberculosis (TB), TEST4TPT aims to reduce barriers to care, support timely TPT initiation, and contribute to improved completion of preventive treatment.

The overall goal of TEST4TPT is to evaluate an integrated, home-based approach to TBI testing using SIILTIBCY (an authorized diagnostic skin test used to detect TBI), community health worker (CHW)-facilitated support, and AI-assisted result reading, with the aim of improving initiation and completion of TPT among close contacts of people newly diagnosed with pulmonary TB disease.

Studienübersicht

Detaillierte Beschreibung

TEST4TPT is a type 2 hybrid effectiveness-implementation study designed to evaluate the effectiveness and implementation of an integrated approach to tuberculosis infection (TBI) testing and tuberculosis preventive treatment (TPT) delivery in Mozambique, Tanzania, and Uganda. The study comprises four complementary sub-studies. Sub-study 1 evaluates the performance and usability of an artificial intelligence (AI)-assisted approach for interpretation of the SIILTIBCY skin test using the SmartPatch and TBConnect application. Sub-study 2 is a pragmatic cluster-randomised trial comparing different models of TBI testing and TPT delivery, including facility- and home-based approaches. Sub-study 3 is a mixed-methods implementation evaluation examining the implementation of these approaches, including their feasibility and acceptability. Sub-study 4 comprises economic and impact assessments to evaluate the costs and broader potential impact of the approaches evaluated in the study.

The technological approach evaluated in Sub-study 1 combines the SIILTIBCY skin test with the SmartPatch and AI-driven TBConnect application. The SmartPatch is an adhesive patch applied to the participant's forearm at the site of SIILTIBCY administration. The patch contains a unique QR code used to link the participant to their record within the TBConnect platform and includes a removable circular section defining the area where the skin test is administered and subsequently read. The SmartPatch remains in place between administration and interpretation of the test.

Sub-study 1 consists of two complementary components: validation of the AI-assisted SIILTIBCY reading approach and an assessment of the usability and user experience of the SmartPatch and TBConnect system. The validation component assesses the performance and agreement of AI-assisted SIILTIBCY interpretation compared with standard interpretation by a trained healthcare worker. The usability component examines use of the technology by healthcare workers and community health workers, as well as participants' experiences of wearing the SmartPatch. A total of 330 household contacts of people with TB, aged five years or older, will participate across Mozambique, Tanzania, and Uganda.

At the follow-up visit, images of the SIILTIBCY administration site are captured through the TBConnect application for AI-assisted interpretation. The AI-assisted approach estimates the size of the induration and provides a corresponding test classification. The SmartPatch therefore supports standardised identification and imaging of the test site, while TBConnect provides the platform through which the images and AI-assisted interpretation are managed.

For validation, the AI-assisted interpretation is compared with a standard SIILTIBCY reading conducted independently by a trained healthcare worker. Both readings are performed on the same skin test and are conducted independently and under blinded conditions. The comparison evaluates the ability of the AI-assisted approach to correctly classify SIILTIBCY results and its agreement with the healthcare-worker reference reading, including agreement in the measured size of induration. During this validation sub-study, participant management and clinical decisions are based on the standard healthcare-worker reading rather than the AI-assisted result.

Sub-study 1 also assesses whether the SmartPatch and TBConnect approach is practical and acceptable to its intended users. Healthcare workers and community health workers with experience using the system are asked about its usability and its integration into routine activities, while participants provide information about their experience of wearing the SmartPatch. These findings complement the validation results by assessing not only whether the AI-assisted approach performs adequately, but also whether it can be feasibly used within the intended implementation context. Findings from Sub-study 1 will inform whether the AI-assisted approach is incorporated into the home-based testing approach evaluated in Sub-study 2.

Sub-study 2 is the main effectiveness evaluation and consists of a pragmatic cluster-randomised trial. Participating health facilities are allocated to three service-delivery approaches: standard-of-care facility-based assessment; facility-based SIILTIBCY testing and reading; or home-based SIILTIBCY testing and reading delivered by community health workers, where permitted by national guidelines. The home-based arm may incorporate AI-assisted interpretation using SmartPatch and TBConnect if this approach demonstrates adequate performance in Sub-study 1. Health facilities are used as clusters to allow consistent implementation of each approach within facility workflows and minimise contamination between study arms.

Sub-study 3 evaluates the implementation of the TEST4TPT approaches using an adapted RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework, complemented by constructs from the Implementation Outcomes Framework. The evaluation considers reach, effectiveness and clinical utility, adoption, implementation, maintenance, feasibility and acceptability. A convergent mixed-methods approach combines implementation data generated during the study with qualitative interviews involving contact persons, community health workers, healthcare workers and TB/National Tuberculosis Programmes (NTP) policymakers or programme managers. This component is intended to provide an understanding of how and why the different TBI testing and TPT delivery approaches work across different settings, alongside the effectiveness results generated in Sub-study 2.

Sub-study 4 comprises the economic and impact assessments of the TEST4TPT approaches. This component evaluates the economic implications of the different TBI testing and TPT delivery strategies and their potential impact, complementing the effectiveness and implementation findings from the other sub-studies.

Studientyp

Interventionell

Einschreibung (Geschätzt)

1804

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

5 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Reside within the catchment area of one of the participating health facilities.
  • Be a close contact, as defined by country guidelines, of a person newly diagnosed with pulmonary tuberculosis disease, irrespective of drug susceptibility.
  • Be aged ≥5 years.
  • Be able to provide written informed consent. For participants below the legal age of consent, written informed consent must be obtained from a parent or legal guardian, with participant assent obtained where required by national regulations.

Exclusion Criteria:

  • Known contraindication to SIILTIBCY according to the manufacturer's instructions for use.
  • People with confirmed TB disease
  • Already on TPT at time of recruitment
  • Previous participation in this sub-study.
  • Presence of skin conditions at the intended injection site that may interfere with SIILTIBCY administration or interpretation of the induration (e.g. extensive dermatitis, burns, scars, or other clinically significant dermatological conditions).
  • Known disease associated with immunosuppression.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Standard of Care

Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive routine facility-based contact investigation and assessment for eligibility for tuberculosis preventive treatment (TPT), according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included, depending on local availability and standard practice

Facility-based identification and assessment of close contacts of people with pulmonary tuberculosis (TB), with assessment for tuberculosis preventive treatment (TPT) eligibility according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included depending on local availability and practice.

Experimental: Facility-based SIILTIBCY testing

Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive facility-based SIILTIBCY testing, (an authorized diagnostic skin test used to detect TBI). SIILTIBCY is administered and subsequently read at the health facility by healthcare workers. Eligible participants are offered tuberculosis preventive treatment (TPT) according to study procedures and prevailing national guidelines.

Close contacts receive SIILTIBCY testing at the health facility. SIILTIBCY is administered intradermally and the test result is read 48-72 hours after administration at the health facility.

Experimental: Home-based SIILTIBCY testing

Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive home-based SIILTIBCY testing and reading delivered by community health workers, where permitted by national guidelines. Artificial Intelligence (AI)-assisted reading using the SmartPatch and TBConnect app may be incorporated if the approach is shown to be sufficiently reliable in Sub-study 1.

Close contacts will receive home-based tuberculosis (TB) infection screening and SIILTIBCY testing delivered by trained community health workers (CHWs), where permitted by national guidelines. CHWs will return to the household 48-72 hours after SIILTIBCY administration to assess the test result. AI-assisted interpretation using the SmartPatch and TBConnect application may be used if supported by the findings of Sub-study 1 and approved for use in the trial. Participants requiring further clinical assessment will be referred or linked to the health facility, and eligible participants will be linked to tuberculosis preventive treatment according to national guidelines.

The SmartPatch and AI-driven TBConnect application are used to support AI-assisted interpretation of the SIILTIBCY skin test. The SmartPatch is applied to the participant's forearm and linked to the TBConnect platform through a unique QR code. Images of the SIILTIBCY administration site are captured using TBConnect for AI-assisted interpretation.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of eligible contacts initiating tuberculosis preventive treatment per index TB patient
Zeitfenster: From sub-study 2 initiation through study completion, approximately 15 months

Number of eligible close contacts who initiate tuberculosis preventive treatment (TPT) per enrolled index TB patient, compared across study arms. This outcome will be used to assess the effectiveness of integrating home-based SIILTIBCY testing and reading into contact investigation compared with standard of care.

From sub-study 2 initiation through study completion, approximately 15 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of contacts identified per TB index patient
Zeitfenster: From sub-study 2 initiation through study completion, approximately 15 months

Number of household or other close contacts identified per TB index patient. The number of contacts identified per index patient will be calculated at cluster level and compared across the three study arms.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts identified
Zeitfenster: From sub-study 2 initiation through study completion, approximately 15 months

Proportion of the estimated contacts of TB index patients who are identified through contact investigation. The proportion will be calculated for each cluster and compared across the three study arms.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts screened for tuberculosis infection
Zeitfenster: From sub-study 2 initiation through study completion, approximately 15 months

Proportion of estimated contacts who undergo tuberculosis infection (TBI) screening. For participants receiving SIILTIBCY, completion of the test requires interpretation within the protocol-defined 48-72-hour reading window after administration.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts initiating tuberculosis preventive treatment
Zeitfenster: From sub-study 2 initiation through study completion, approximately 15 months

Proportion of estimated contacts who initiate tuberculosis preventive treatment (TPT). TPT initiation is recorded using the treatment start date and will be compared across study arms.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts completing tuberculosis preventive treatment
Zeitfenster: Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

Proportion of estimated contacts who complete tuberculosis preventive treatment (TPT). Treatment completion status and completion date will be recorded and the outcome compared across study arms.

Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)
Occurrence of adverse events
Zeitfenster: Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

Proportion of participants experiencing one or more adverse events during TBI testing or TPT, including the type, severity and relatedness of adverse events to the intervention, where applicable.

Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. April 2027

Primärer Abschluss (Geschätzt)

1. Dezember 2028

Studienabschluss (Geschätzt)

30. April 2029

Studienanmeldedaten

Zuerst eingereicht

29. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. November 2026

Zuerst gepostet (Tatsächlich)

13. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data underlying study publications may be made available in accordance with the TEST4TPT Data Management Plan, applicable ethical and legal requirements, and relevant data-sharing agreements. Shared datasets will exclude direct and indirect personal identifiers to minimise the risk of participant re-identification.

IPD-Sharing-Zeitrahmen

IPD and supporting information will be made available following publication of the primary study findings. Study records will be retained for a minimum of five years after publication of the final study results, or longer where required by sponsor policies, institutional requirements, or applicable national ethics, data protection, or privacy regulations.

IPD-Sharing-Zugriffskriterien

Fully de-identified datasets may be made openly available through a suitable trusted research data repository. Where participant-level datasets cannot be made openly accessible because of ethical or legal restrictions, qualified external researchers may request access by submitting a data access request describing the intended scientific use. Requests will be reviewed by the study Principal Investigators prior to approval. Access will be subject to participant consent, ethical approvals, institutional policies, sponsor requirements, and applicable data protection regulations.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ANALYTIC_CODE

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren